mRNA overexpression of prolyl hydroxylase PHD3 is inversely related to nuclear grade in renal cell carcinoma

Kampantais,Spyridon; Kotoula,Vasiliki; Kounatidis,Ilias; Vakalopoulos,Ioannis; Gourvas,Victoras; Lymperi,Stefania; Dimitriadis,Georgios

doi:10.3892/mco.2020.2076

mRNA overexpression of prolyl hydroxylase PHD3 is inversely related to nuclear grade in renal cell carcinoma

Authors:
- Spyridon Kampantais
- Vasiliki Kotoula
- Ilias Kounatidis
- Ioannis Vakalopoulos
- Victoras Gourvas
- Stefania Lymperi
- Georgios Dimitriadis
View Affiliations

Affiliations: 1st Department of Urology, Gennimatas General Hospital, Aristotle University of Thessaloniki, Thessaloniki 54635, Greece, Department of Pathology, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine, Thessaloniki 54124, Greece, Cell Biology, Development and Genetics Laboratory, Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK, Private Pathology Lab ‘Victoras Gourvas’, Thessaloniki 54624, Greece, Private Diagnostic Andrology Lab, Thessaloniki 54623, Greece
Published online on: June 26, 2020 https://doi.org/10.3892/mco.2020.2076
Article Number: 11
Copyright: © Kampantais et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate the relative mRNA expression levels of genes involved in the hypoxia inducible factor (HIF) signalling pathway in renal cell carcinoma (RCC) and to analyse their associations with clinicopathological parameters and survival outcomes. Reverse transcription‑quantitative PCR was used to quantify the mRNA expression levels of HIF‑1α, HIF‑2α, prolyl hydroxylase (PHD)1, PHD2 and PHD3 in formalin‑fixed paraffin‑embedded (FFPE) tumour tissue samples from 41 patients with RCC, including 33 cases of clear cell RCC (ccRCC). FFPE samples of corresponding adjacent normal kidney tissues were used as a comparison. mRNA expression levels were analysed in regard to clinical parameters, histological type, stage, nuclear grade, cancer specific survival and overall survival. Compared with adjacent normal kidney tissue, HIF‑1α levels were lower in 16/33 ccRCC samples (48.48%), while HIF‑2α, PHD1 and PHD2 levels did not exhibit a specific expression pattern. By contrast, the PHD3 mRNA level was higher in 29/33 (87.87%) of the tumour samples. HIF‑1α was positively associated with HIF‑2α, PHD1 and PHD2. HIF‑2α levels were associated with PHD1, PHD2 and PHD3, while PHD3 was strongly associated with PHD2. PHD3 mRNA levels were inversely associated with nuclear grade (P=0.015). However, in univariate analysis, PHD3 was not associated with cancer‑specific or overall survival rates. The present findings suggest an important involvement of PHD3 in ccRCC, since PHD3 mRNA expression was inversely associated with nuclear grade. However, PHD3 mRNA levels did not have an independent prognostic value. Further studies are required to investigate whether PHD3 could be used as either a therapeutic target or prognostic marker.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010.PubMed/NCBI View Article : Google Scholar
2	Sun M, Marconi L, Eisen T, Escudier B, Giles RH, Haas NB, Harshman LC, Quinn DI, Larkin J, Pal SK, et al: Adjuvant vascular endothelial growth factor-targeted therapy in renal cell carcinoma: A systematic review and pooled analysis. Eur Urol. 74:611–620. 2018.PubMed/NCBI View Article : Google Scholar
3	Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, et al: The Heidelberg classification of renal cell tumours. J Pathol. 183:131–133. 1997.PubMed/NCBI View Article : Google Scholar
4	Lane BR and Kattan MW: Prognostic models and algorithms in renal cell carcinoma. Urol Clin North Am. 35:613–625, vii. 2008.PubMed/NCBI View Article : Google Scholar
5	Kimbro KS and Simons JW: Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer. 13:739–749. 2006.PubMed/NCBI View Article : Google Scholar
6	Vaupel P, Kelleher DK and Höckel M: Oxygen status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol. 28 (Suppl 8):29–35. 2001.PubMed/NCBI View Article : Google Scholar
7	Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER and Ratcliffe PJ: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399:271–275. 1999.PubMed/NCBI View Article : Google Scholar
8	Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, Wykoff CC, Maher ER, Harris AL, Ratcliffe PJ and Maxwell PH: HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron. Cancer Cell. 1:459–468. 2002.PubMed/NCBI View Article : Google Scholar
9	De Luise M, Girolimetti G, Okere B, Porcelli AM, Kurelac I and Gasparre G: Molecular and metabolic features of oncocytomas: Seeking the blueprints of indolent cancers. Biochim Biophys Acta Bioenerg. 1858:591–601. 2017.PubMed/NCBI View Article : Google Scholar
10	Gerard GF, D'Alessio JM, Kotewicz ML and Noon MC: Influence on stability in Escherichia coli of the carboxy-terminal structure of cloned Moloney murine leukemia virus reverse transcriptase. DNA. 5:271–279. 1986.PubMed/NCBI View Article : Google Scholar
11	Kotewicz ML, D'Alessio JM, Driftmier KM, Blodgett KP and Gerard GF: Cloning and overexpression of Moloney murine leukemia virus reverse transcriptase in escherichia coli. Gene. 35:249–258. 1985.PubMed/NCBI View Article : Google Scholar
12	Marathe SV and McEwen JE: Vectors with the gus reporter gene for identifying and quantitating promoter regions in Saccharomyces cerevisiae. Gene. 154:105–107. 1995.PubMed/NCBI View Article : Google Scholar
13	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008.PubMed/NCBI View Article : Google Scholar
14	Gourvas V, Sifakis S, Dalpa E, Soulitzis N, Koukoura O and Spandidos DA: Reduced placental prolyl hydroxylase 3 mRNA expression in pregnancies affected by fetal growth restriction. BJOG. 117:1635–1642. 2010.PubMed/NCBI View Article : Google Scholar
15	Aprelikova O, Chandramouli GV, Wood M, Vasselli JR, Riss J, Maranchie JK, Linehan WM and Barrett JC: Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors. J Cell Biochem. 92:491–501. 2004.PubMed/NCBI View Article : Google Scholar
16	Rantanen K, Pursiheimo JP, Hogel H, Miikkulainen P, Sundstrom J and Jaakkola PM: p62/SQSTM1 regulates cellular oxygen sensing by attenuating PHD3 activity through aggregate sequestration and enhanced degradation. J Cell Sci. 126:1144–1154. 2013.PubMed/NCBI View Article : Google Scholar
17	Jaakkola PM and Rantanen K: The regulation, localization, and functions of oxygen-sensing prolyl hydroxylase PHD3. Biol Chem. 394:449–457. 2013.PubMed/NCBI View Article : Google Scholar
18	Högel H, Miikkulainen P, Bino L and Jaakkola PM: Hypoxia inducible prolyl hydroxylase PHD3 maintains carcinoma cell growth by decreasing the stability of p27. Mol Cancer. 14(143)2015.PubMed/NCBI View Article : Google Scholar
19	Miikkulainen P, Hogel H, Rantanen K, Suomi T, Kouvonen P, Elo LL and Jaakkola PM: HIF prolyl hydroxylase PHD3 regulates translational machinery and glucose metabolism in clear cell renal cell carcinoma. Cancer Metab. 5(5)2017.PubMed/NCBI View Article : Google Scholar
20	Sato E, Torigoe T, Hirohashi Y, Kitamura H, Tanaka T, Honma I, Asanuma H, Harada K, Takasu H, Masumori N, et al: Identification of an immunogenic CTL epitope of HIFPH3 for immunotherapy of renal cell carcinoma. Clin Cancer Res. 14:6916–6923. 2008.PubMed/NCBI View Article : Google Scholar
21	Tanaka T, Kitamura H, Torigoe T, Hirohashi Y, Sato E, Masumori N, Sato N and Tsukamoto T: Autoantibody against hypoxia-inducible factor prolyl hydroxylase-3 is a potential serological marker for renal cell carcinoma. J Cancer Res Clin Oncol. 137:789–794. 2011.PubMed/NCBI View Article : Google Scholar
22	Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ and Gleadle JM: Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem. 279:38458–38465. 2004.PubMed/NCBI View Article : Google Scholar
23	Tanaka T, Torigoe T, Hirohashi Y, Sato E, Honma I, Kitamura H, Masumori N, Tsukamoto T and Sato N: Hypoxia-inducible factor (HIF)-independent expression mechanism and novel function of HIF prolyl hydroxylase-3 in renal cell carcinoma. J Cancer Res Clin Oncol. 140:503–513. 2014.PubMed/NCBI View Article : Google Scholar
24	Kroeze SG, Vermaat JS, van Brussel A, van Melick HH, Voest EE, Jonges TG, van Diest PJ, Hinrichs J, Bosch JL and Jans JJ: Expression of nuclear FIH independently predicts overall survival of clear cell renal cell carcinoma patients. Eur J Cancer. 46:3375–3382. 2010.PubMed/NCBI View Article : Google Scholar
25	Salama R, Masson N, Simpson P, Sciesielski LK, Sun M, Tian YM, Ratcliffe PJ and Mole DR: Heterogeneous effects of direct hypoxia pathway activation in kidney cancer. PLoS One. 10(e0134645)2015.PubMed/NCBI View Article : Google Scholar
26	Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma Y, Patel N, Yell P, et al: Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 539:112–117. 2016.PubMed/NCBI View Article : Google Scholar
27	Wallace EM, Rizzi JP, Han G, When PM, Cao Z, Du X, Cheng T, Czerwinski RM, Dixon DD, Goggin BS, et al: A small-molecule antagonist of HIF2α is efficacious in preclinical models of renal cell carcinoma. Cancer Res. 76:5491–5500. 2016.PubMed/NCBI View Article : Google Scholar